Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-17

Study Completion Date

2020-05-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomised, double-blind, placebo-controlled, multicentre, multinational, prospective study in patients with operable chronic thromboembolic pulmonary hypertension (CTEPH) prior to pulmonary endarterectomy (PEA) with high preoperative pulmonary vascular resistance (PVR). Patients will be randomised in a 1:1 ratio to receive riociguat or matching placebo for 3 months before undergoing PEA. The primary objective of this study is to assess the efficacy of riociguat on preoperative PVR compared to placebo in patients with operable CTEPH.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH

NCT04954742

Primary Pulmonary Arterial Hypertension Chronic Thromboembolic Pulmonary Hypertension

TERMINATED PHASE4

Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )

NCT02117791

Hypertension, Pulmonary

COMPLETED

Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH

NCT05339087

Pulmonary Vascular Disorder Primary Pulmonary Hypertension Systemic Sclerosis +1 more

TERMINATED PHASE2

Riociguat-Discontinue Effects on Right HEART in CTEPH (RED-HEART)

NCT06922240

Chronic Thromboembolic Pulmonary Hypertension

RECRUITING PHASE3

Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

NCT01784562

Hypertension, Pulmonary

NO_LONGER_AVAILABLE

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Thromboembolic Pulmonary Hypertension CTEPH

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Double-blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Riociguat

Patients will receive riociguat for 3 months followed by pulmonary endarterectomy.

Group Type ACTIVE_COMPARATOR

Riociguat

Intervention Type DRUG

Riociguat will be initiated at 1 mg tid. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.

Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability.

Pulmonary endarterectomy

Intervention Type PROCEDURE

PEA will be performed at the end of medical treatment (Day 90)

Placebo

Patients will receive placebo for 3 months followed by pulmonary endarterectomy.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo will be given analogue to riociguat with matching tablets.

Pulmonary endarterectomy

Intervention Type PROCEDURE

PEA will be performed at the end of medical treatment (Day 90)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Riociguat

Riociguat will be initiated at 1 mg tid. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.

Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability.

Intervention Type DRUG

Placebo

Placebo will be given analogue to riociguat with matching tablets.

Intervention Type DRUG

Pulmonary endarterectomy

PEA will be performed at the end of medical treatment (Day 90)

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Adempas BAY 63-2521 PEA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Is a male or nonpregnant and nonlactating female patient aged from 18 to 80 years, both inclusive
* Is diagnosed with operable CTEPH and anticipating symptomatic and/or prognostic benefit from PEA
* Has pulmonary vascular resistance (PVR) \>800 dyn·s·cm-5
* Has undergone right heart catheterisation not more than 180 days before randomisation visit
* Has been treated with anticoagulants for at least 90 days before randomisation visit
* Has ability to swallow oral medication
* Has ability and willingness to participate and access the health facility
* Is capable of understanding the written informed consent and provides signed and witnessed written informed consent
* Female patient must be either surgically sterile, postmenopausal (no menses for the previous 12 months), or must be practicing an effective method of birth control as determined by the investigator (eg, oral contraceptives, double barrier methods, hormonal injectable or implanted contraceptives, tubal ligation, or male partner with vasectomy or complete abstinence)

Exclusion Criteria

* Has unstable disease in need of urgent PEA surgery as determined by the treating physician
* Has known hypersensitivity, allergic, or adverse reactions to riociguat or any of the excipients comprising riociguat tablets.
* Has known active hepatitis A IgM (HAV-IgM), hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCV Ab)
* Is human immunodeficiency virus positive
* Has pulmonary veno-occlusive disease
* Has symptomatic hypotension
* Has symptomatic carotid disease
* Has significant coronary atherosclerotic disease in need of intervention
* Has severe left heart disease in need of intervention
* Has redo sternotomy
* Has received any background therapy for pulmonary arterial hypertension (PAH) in the preceding 30 days before randomisation visit including endothelin receptor antagonists (ERAs), phosphodiesterase 5 (PDE5) inhibitors, or prostanoids
* Is receiving nitrates, nitric oxide donors (e.g. amyl nitrite), ERAs, prostanoids, specific PDE5 inhibitors, nonspecific phosphodiesterase inhibitors (e.g. dipyridamole, theophylline)
* Is receiving strong cytochrome P450 (CYP) and P-glycoprotein/breast cancer resistance protein inhibitors
* Is receiving strong CYP3A inducers
* Has creatinine clearance \<15 mL/min or on any form of dialysis
* Has severe hepatic impairment classified as Child-Pugh C
* Has received an investigational drug within the past 4 weeks before randomisation visit
* Is a lactating or pregnant (as demonstrated by a serum pregnancy test) woman, and not willing to take measures for not to become pregnant during the 3 months treatment study period and one month after the last dose of study drug administered
* Has smoked or used tobacco in any form, including snuff or chewing within 3 months prior to randomisation visit
* Has idiopathic interstitial pneumonitis

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No